Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 1
2020 1
2021 4
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic significance of procalcitonin in small cell lung cancer.
Ichikawa K, Watanabe S, Miura S, Ohtsubo A, Shoji S, Nozaki K, Tanaka T, Saida Y, Kondo R, Hokari S, Aoki N, Ohshima Y, Koya T, Kikuchi T. Ichikawa K, et al. Among authors: ohtsubo a. Transl Lung Cancer Res. 2022 Jan;11(1):43-52. doi: 10.21037/tlcr-21-838. Transl Lung Cancer Res. 2022. PMID: 35242626 Free PMC article.
Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients.
Kushiro K, Watanabe S, Goto Y, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Tanaka T, Saida Y, Sato Y, Ota T, Koshio J, Hayashi Y, Miyabayashi T, Matsumoto N, Ichikawa K, Koyama K, Kikuchi T. Kushiro K, et al. Among authors: ohtsubo a. Transl Lung Cancer Res. 2022 Sep;11(9):1858-1865. doi: 10.21037/tlcr-22-225. Transl Lung Cancer Res. 2022. PMID: 36248339 Free PMC article.
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer.
Takahashi M, Watanabe S, Suzuki R, Arita M, Sato K, Sato M, Sekiya Y, Abe Y, Fujisaki T, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Saida Y, Hokari S, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. Takahashi M, et al. Among authors: ohtsubo a. Cancer Immunol Immunother. 2022 Jun;71(6):1357-1369. doi: 10.1007/s00262-021-03078-0. Epub 2021 Oct 17. Cancer Immunol Immunother. 2022. PMID: 34657194 Free PMC article.
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).
Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T. Watanabe S, et al. Among authors: ohtsubo a. Cancers (Basel). 2022 Dec 29;15(1):204. doi: 10.3390/cancers15010204. Cancers (Basel). 2022. PMID: 36612200 Free PMC article.
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302).
Shoji S, Miura S, Watanabe S, Ohtsubo A, Nozaki K, Saida Y, Ichikawa K, Kondo R, Tanaka T, Koyama K, Tanaka H, Okajima M, Abe T, Ota T, Ishida T, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Shoji S, et al. Among authors: ohtsubo a. Transl Lung Cancer Res. 2022 Jul;11(7):1359-1368. doi: 10.21037/tlcr-22-89. Transl Lung Cancer Res. 2022. PMID: 35958345 Free PMC article.
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity.
Arita M, Watanabe S, Aoki N, Kuwahara S, Suzuki R, Goto S, Abe Y, Takahashi M, Sato M, Hokari S, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Hayashi M, Ohshima Y, Kabasawa H, Hosojima M, Koya T, Saito A, Kikuchi T. Arita M, et al. Among authors: ohtsubo a. Sci Rep. 2021 Jan 12;11(1):750. doi: 10.1038/s41598-020-80853-6. Sci Rep. 2021. PMID: 33437029 Free PMC article.
Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.
Sato Y, Watanabe S, Ota T, Kushiro K, Fujisaki T, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Hayashi M, Ishikawa H, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Ohshima Y, Koya T, Kikuchi T. Sato Y, et al. Among authors: ohtsubo a. Transl Lung Cancer Res. 2021 Jul;10(7):3132-3143. doi: 10.21037/tlcr-21-198. Transl Lung Cancer Res. 2021. PMID: 34430353 Free PMC article.
The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events.
Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. Fujisaki T, et al. Among authors: ohtsubo a. Front Oncol. 2021 Sep 24;11:704475. doi: 10.3389/fonc.2021.704475. eCollection 2021. Front Oncol. 2021. PMID: 34631533 Free PMC article.
Frequent Germline and Somatic Single Nucleotide Variants in the Promoter Region of the Ribosomal RNA Gene in Japanese Lung Adenocarcinoma Patients.
Ohashi R, Umezu H, Sato A, Abé T, Kondo S, Daigo K, Sato S, Hara N, Miyashita A, Ikeuchi T, Motoyama T, Kishi M, Nagaoka T, Horiuchi K, Shiga A, Okuda S, Sekiya T, Ohtsubo A, Ichikawa K, Kagamu H, Kikuchi T, Watanabe S, Tanuma JI, Schraml P, Hamakubo T, Tsuchida M, Ajioka Y. Ohashi R, et al. Among authors: ohtsubo a. Cells. 2020 Nov 3;9(11):2409. doi: 10.3390/cells9112409. Cells. 2020. PMID: 33153169 Free PMC article.
13 results